Physicians' Academy for Cardiovascular Education

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

Greater intake of sodium and protein may predispose to deeper fall in GFR after start of SGLT2i

3' education - Sep. 21, 2022 - Marta Seghieri, MD

Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage

3' education - Sep. 21, 2022 - Prof. Peter Rossing, MD

Unexpected findings when comparing DOAC with VKA in rheumatic AF

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

Understanding the effects of ARNI in acute MI

3' education - Sep. 15, 2022 - Otavio Berwanger, MD, PhD

What have we learned from previous CETP inhibitor outcome trials?

10' education - Sep. 15, 2022 - Prof. Stephen Nicholls, MD

Meta-analysis on effects of statins on muscle symptoms

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

Finding a place for fish oil in CVD prevention

10' education - Sep. 7, 2022 - Prof. Chris Packard, PhD

Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD?

3' education - Sep. 5, 2022 - Prof. Marco Valgimigli, MD, PhD

Phenotypic changes associated with aortic stenosis detected by AI-algorithm

3' education - Sep. 5, 2022 - Prof. Geoffrey Strange, MD, PhD

Increased coronary atherosclerotic plaque activity is associated with all-cause mortality

3' education - Sep. 5, 2022 - Prof. David Newby, PhD

Challenging results in trial evaluating PCI in severe ischemic LV dysfunction

3' education - Aug. 30, 2022 - Prof. Divaka Perera, MD

Long-term use of PCSK9i reduces CV events, including CV death

3' education - Aug. 29, 2022 - Michelle O'Donoghue, MD

FXIa inhibition in non-cardioembolic stroke patients

3' education - Aug. 29, 2022 - Ashkan Shoamanesh, MD

Screening using a smartphone-app more than doubles detection rate of AF

3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD

A community-based screening trial for CVD with cardiac CT scan

3' education - Aug. 28, 2022 - Prof. Axel Diederichsen, MD

SGLT2i improves outcomes in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Combination therapy with loop diuretic and acetazolamide improves decongestion in acute HF

3' education - Aug. 27, 2022 - Prof. Wilfried Mullens, MD, PhD

Totality of evidence of SGLT2 inhibition in HF

3' education - Aug. 27, 2022 - Muthiah Vaduganathan, MD

All patients with HF regardless of EF benefit from SGLT2i

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

Aortic valve phenotype in HoFH shifted from to calcified aortic stenosis since statins

Literature - Sep. 26, 2022 - Bélanger AM, et al. - Eur Heart J. 2022

Severe calcified aortic stenosis (AS) is an important long-term complication of homozygous FH (HoFH). However, it is unclear whether the introduction of statins has affected the AS phenotype in patients with HoFH. This systematic review provides more insight.

Inflammation stronger predictor of future MACE in statin-treated CKD patients than LDL-c

Literature - Sep. 25, 2022 - Ridker PM, et al. - Eur Heart J. 2022

Using data from the CANTOS trial, the investigators assessed the relative contributions of hyperlipidemia and inflammation to CV clinical outcomes in atherosclerosis patients on statin therapy, stratified by eGFR.

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

EASD 2022 "Any patient that has HFmrEF or HFpEF is going to benefit from dapaglifozin regardless of glycemic status and regardless of background diabetes therapy", says Prof. Jhund.

Reduced muscle fat infiltration in anterior thigh muscle with GLP-1RA in overweight or obesity

News - Sep. 22, 2022

EASD 2022 A prespecified secondary analysis was performed to investigate whether muscle fat infiltration -associated with increased risk of HF- can be modified by treatment with liraglutide in patients with overweight or obesity.

Effect of SGLT2i on shifts in KDIGO CKD risk groups in T2DM patients

News - Sep. 22, 2022

EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.

New guidelines on CV assessment of patients undergoing non-cardiac surgery

News - Sep. 21, 2022

The European Heart Journal has published the 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.

More remission and less development of metabolic syndrome with GLP-1RA

News - Sep. 21, 2022

EASD 2022 A post hoc analysis of the STEP 5 trial showed that a greater proportion of adults with overweight achieved remission of metabolic syndrome and a smaller proportion developed metabolic syndrome with semaglutide vs. placebo.

Greater intake of sodium and protein may predispose to deeper fall in GFR after start of SGLT2i

3' education - Sep. 21, 2022 - Marta Seghieri, MD
It is useful to know whether sodium and protein intake affect the early GFR dip that may be observed after initiation with SGLT2i, says Marta Seghieri. She shares the findings of a pilot study.

EASD 2022 It is useful to know whether sodium and protein intake affect the early GFR dip that may be observed after initiation with SGLT2i, says Marta Seghieri. She shares the findings of a pilot study.

Pilot study suggests association of sodium and protein intake with early GFR dip after SGLT2i initiation

News - Sep. 21, 2022

EASD 2022 It is not known whether a higher intake of sodium and protein may lead to a higher extent of early dip in GFR in T2DM patients who started an SGLT2 inhibitor. A pilot study was undertaken with 28 subjects.

Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage

3' education - Sep. 21, 2022 - Prof. Peter Rossing, MD
**EASD 2022** A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk.

EASD 2022 A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk.

GLP-1RA consistently reduces risk of MACE across kidney function subgroups

News - Sep. 21, 2022

EASD 2022 This pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 showed that that semaglutide consistently reduced the risk of MACE across eGFR and UACR subgroups in patients with T2DM who are at high CV risk.

Relationships of CRP and C-peptide with CV events and all-cause mortality in new onset T2DM

News - Sep. 21, 2022

EASD 2022 In patients with new onset T2DM in the DD2 cohort, high CRP was a better marker of all-cause mortality than future CV events, whereas high C-peptide was a better marker of increased CV risk.